Evidence map›Paper›PMID 31938683›Full record

ArticleDiabetology international2020

Incidence and causes of mildly to moderately elevated aminotransferase in Japanese patients with type 2 diabetes.

Chia-Hsien Chang, Motonobu Sakaguchi

Open access · greenAbstract read
In one paragraph

Article in Diabetology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chia-Hsien ChangGlobal Patient Safety Evaluation Japan, Takeda Pharmaceutical Company Limited, 1-1, Doshomachi-4-Chome, Chuo-ku, Osaka, 540-8645 Japan.ORCID 0000-0002-6988-7944
Motonobu SakaguchiGlobal Patient Safety Evaluation Japan, Takeda Pharmaceutical Company Limited, 1-1, Doshomachi-4-Chome, Chuo-ku, Osaka, 540-8645 Japan.
Takeda (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo identify the association of type 2 diabetes (T2DM) and liver disease with elevated ALT and factors associated with increased ALT in patients with and without T2DM. DESIGN AND

settingWe performed a retrospective study in adults with ≥ 2 claims for blood tests recorded in the Medical Data Vision claims database between 2010 and 2016.

participantsPatients were entered into T2DM and non-DM groups based on diagnosis and medication claim codes. PRIMARY OUTCOME MEASURE: The primary endpoint was the first follow-up ALT elevation over three times the normal value, and etiologies were categorized by subsequent diagnoses. We estimated the ALT elevation incidence and association with T2DM using Poisson regression and Cox proportional hazard models.

resultsWe identified 3161 cases of elevated ALT in 104,903 patients (follow-up, 280,659 patient-years). The age- and sex-adjusted incidence of elevated ALT in the T2DM group (13.47 per 1000 patient-years; 95% confidence interval (CI) 12.53-14.48) was significantly higher than that in the non-DM group (8.43 per 1000 patient-years; 95% CI 7.72-9.20,

conclusionT2DM is strongly associated with increased liver enzymes secondary to fatty liver. The causes of liver enzyme abnormalities were not fully characterized due to a high proportion of unexplained ALT elevation.

Indexed as

Alanine transaminaseDiabetes mellitusEpidemiologyJapanLiver diseases

Identifiers

PMID31938683
PMCPMC6942058
OpenAlexW2968418137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.